Author:
Hirlekar Rajashree,Bhairy Srinivas,Momin Alfiha
Abstract
Purpose: The present study was aimed at preparing stable dry adsorbed nanoparticles (DANs) of curcumin (CUR) and piperine (PIP) loaded nanostructured lipid carriers (NLCs).
Methods: CUR and PIP-loaded NLCs (CP NLCs) were prepared by modified hot-melt emulsification using precirol ATO5 (PRE) as solid lipid, labrafac lipophile WL1349 (LAF) as liquid lipid, and a combination of tween 80 (T80) with gelucire 50/13 (G50/13) as surfactants. The NLCs system was subjected to physical stability, particle size, zeta potential, thermal behaviour, crystallinity study and in-vitro drug release. Further, an evaporative drying technique converted the NLC system into stable DANs by adsorbing onto mannitol (Pearlitol 200SD). The DANs were characterized for redispersion properties, particle size, flow properties and in-vitro drug release. The stability studies were carried out for 30 days.
Results: The optimized CP NLCs were of imperfect type and had a mean particle size of 248.5 ± 12.8 nm (size distribution of 0.216 ± 0.021), a zeta potential of -9.03 ± 0.53 mV, an entrapment efficiency (EE) of 99.80 ± 0.21% (CUR), 100.05 ± 0.07% (PIP) with a drug recovery of 99.70 ± 0.21% (CUR) and 100.36 ± 0.12% (PIP). The X-ray diffraction pattern and endothermic peaks confirmed the encapsulation of actives in lipid matrices. The in-vitro drug release showed controlled release for 24 h. The optimized DANs led to maximum redispersion and retained a particle size of 268.4 ± 23.1 nm (distribution 0.235 ± 0.037) with controlled release similar to CP NLCs. The CP NLCs DANs showed reasonable stability for 30 days.
Conclusions: The developed CP NLCs DANs showed a controlled release profile, and the adsorption technique can be used to improve the stability of NLC dispersion. The DANs can be offered in patient-friendly dosage forms such as sachets, capsules, and compressed tablets.
Publisher
BSP Books Private Limited
Subject
Pharmacology (medical),Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,Pharmacy
Reference43 articles.
1. Bruce JA. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci. 1993 Jan 22;82(10):979-87. DOI: https://doi.org/10.1002/jps.2600821008.
2. Christopher J, William N. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 2001 Oct 1;50(1):S127-47. DOI: https://doi.org/10.1016/S0169-409X(01)00182-X.
3. Gordon L, Hans L, Vinod S, Vinod S, John C. A theoretical basis for a biopharmaceutic drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995 Mar 1;12(3):413-20. DOI: https://doi.org/10.1023/a:1016212804288.
4. Moorthi C, Senthil C, Kathiresan K. Synergistic anti-cancer activity of curcumin and bio-enhancers combination against various cancer cell lines. Int J Pharm Pharm Sci. 2014 Jan 1;6(1):901-3.
5. Ann-Lii C, Chih-Hung H, Jen-Kun L, Mow-Ming H, Yunn-Fanh H, Tzung-Shiahn S, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 May 2;21(4B): 2895-900.